TuisCIPLA • NSE
add
Cipla Ltd
Vorige sluiting
₹1 502,80
Dagwisseling
₹1 480,00 - ₹1 510,50
Jaarwisseling
₹1 335,00 - ₹1 702,05
Markkapitalisasie
1,22 bn INR
Gemiddelde volume
1,85 m
P/V-verhouding
23,11
Dividend-opbrengs
0,86%
Primêre beurs
NSE
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (INR) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 65,98 mjd | 6,89% |
Bedryfskoste | 31,80 mjd | 15,17% |
Netto inkomste | 12,22 mjd | 30,12% |
Netto winsgrens | 18,52 | 21,76% |
Wins per aandeel | 15,12 | 30,12% |
EBITDA | 15,06 mjd | 11,75% |
Effektiewe belastingkoers | 18,70% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (INR) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 80,93 mjd | 3,81% |
Totale bates | 373,87 mjd | 14,27% |
Totale aanspreeklikheid | 60,98 mjd | 3,08% |
Totale ekwiteit | 312,89 mjd | — |
Uitstaande aandele | 807,62 m | — |
Prys om te bespreek | 3,89 | — |
Opbrengs op bates | — | — |
Opbrengs op kapitaal | 10,13% | — |
Kontantvloei
Netto kontantverandering
| (INR) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 12,22 mjd | 30,12% |
Kontant van bedrywe | — | — |
Kontant van beleggings | — | — |
Kontant van finansiering | — | — |
Netto kontantverandering | — | — |
Beskikbare kontantvloei | — | — |
Meer oor
Cipla Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Cipla primarily focuses on developing medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, paediatric and various other medical conditions. Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer in India. Wikipedia
HUB
Gestig
1935
Hoofkwartier
Webwerf
Werknemers
27 764
